MedPath

Study to Evaluate the Effect of a Nu Skin Product and Device for Brown Spots

Phase 4
Completed
Conditions
Hyperpigmentation
Interventions
Other: Nu Skin Product
Other: CeraVe moisturizer
Other: Cosmetic instrument
Registration Number
NCT01149876
Lead Sponsor
Massachusetts General Hospital
Brief Summary

The purpose of this study is to determine whether a topical Nu Skin product with or without a galvanic spa device improves brown spots on the face. The Nu Skin product will be compared to an over the counter moisturizer and tretinoin cream.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
80
Inclusion Criteria
  • Able to understand and sign informed consent.
  • Able to complete study and comply with study procedures.
  • Caucasian female ages 25-55.
  • Presence of photodamage and lentigines of II-III on the Glogau Photoaging
  • Must be willing to avoid laser and light treatments, treatments with filler, chemical peels, microdermabrasion, Botox or any other cosmetic treatment to the face during the duration of the study.
  • Must be willing to avoid changing topical moisturizers and cosmetics during the study.
  • Able to stop any alpha or beta hydroxy acids, topical retinol or retinoid derivatives, topical antioxidants, or any topical product that may interfere with the study 2 weeks prior to the study.
Exclusion Criteria
  • Cosmetic treatment of face, such as laser or light treatment, filler, Botox, microdermabrasion, or chemical peels 6 months prior to study or during study.
  • Current smoker.
  • Pregnant, nursing, or planning to become pregnant during study.
  • Currently taking drugs including oral retinoids or any other medication with a known clinically significant drug interaction with topical tretinoin.
  • Known hypersensitivity to retinoids. History of severe retinoid dermatitis.
  • History of substance abuse, mental dysfunction, or other factors limiting ability to cooperate with study.
  • Concurrent participation in another clinical study or participation 30 days prior to enrollment that includes exposure to an investigational drug that would interfere with this study.
  • Any disease or condition which would interfere with study participation or unduly increase risk.
  • Presence of an electrically sensitive support system such as a pacemaker.
  • Known history of epilepsy.
  • Presence of metal implants or metal braces on teeth.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Nu Skin ProductNu Skin Product-
Nu Skin product with galvanic spa systemNu Skin Product-
Tretinoin cream 0.05Tretinoin cream 0.05-
Nu Skin product with galvanic spa systemCosmetic instrument-
over the counter moisturizerCeraVe moisturizer-
Primary Outcome Measures
NameTimeMethod
Change in Hyperpigmentation of the Facebaseline to 16 weeks

Primary outcome measure will be change in hyperpigmentation of baseline compared to week 16.

Hyperpigmentation will be measured clinically using a 0-6 scale where 0 is no hyperpigmentation and 6 is very severe hyperpigmentation.

Secondary Outcome Measures
NameTimeMethod
Change in Rhytidesbaseline to week 16

Secondary outcome measures will be change in rhytides of baseline compared to week 16.

Rhytides will be assessed clinically using a 0-6 scale where 0 is no lines and 6 is very deep lines.

Trial Locations

Locations (1)

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath